Introduction: Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, multisystem disease characterized by neuropathy and cardiomyopathy (1). RNA interference therapy with patisiran, administered at 0.3 mg/kg intravenously every three weeks, has shown durable reductions (~82%) in serum transthyretin (TTR) over 24 months, along with
3 Reached
Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure
150 Reached
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Patient with History of Atrial Fibrillation
519 Reached3 Likes
Young Girl Presented with Irritability and Abnormal Behavior
2253 Reached10 Comments4 Likes